immunotherapies

Pfizer Inc (NYSE: PFE) is in early discussions to purchase biotechnology company Seagen Inc (NASDAQ: SGEN), The Wall Street Journal reported late on Sunday, citing people familiar with the matter. The deal would reportedly be valued at more than $30 billion and will help Pfizer...